文献速递皮肤肿瘤

微卫星灶在黑色素瘤中的预后作用及其在美国癌症联合委员会分类系统中的意义:一项队列研究

Prognostic role of microsatellites in melanoma and implications in the American Joint Committee on Cancer classification system: A cohort study.
PubMed 文献 · J Am Acad Dermatol · 2022-10-17

这项1998至2019年的回顾性双中心队列研究纳入5216例侵袭性皮肤黑色素瘤患者,其中108例(2.1%)在初始分期时存在微卫星灶。生存分析显示微卫星灶是总生存期、黑色素瘤特异性生存期和无病生存期较差的独立危险因素,风险比分别为1.57、1.76和1.76。在III期患者的分层分析中,伴有微卫星灶的IIIB期患者5年总生存率为35%(95%CI,17.3%-73.4%),黑色素瘤特异性生存率为45%(95%CI,23.1-87.5)。

要点

  • 5216例侵袭性皮肤黑色素瘤患者中108例(2.1%)在初始分期时存在微卫星灶。
  • 微卫星灶是总生存期、黑色素瘤特异性生存期和无病生存期较差的独立危险因素。
  • 伴有微卫星灶的IIIB期患者5年总生存率为35%,黑色素瘤特异性生存率为45%。

核心结论

  • 微卫星灶与其他不良黑色素瘤预后因素相关。
  • 多变量Cox回归分析显示微卫星灶是总生存期、黑色素瘤特异性生存期和无病生存期较差的独立危险因素。
  • 伴有微卫星灶的IIIB期黑色素瘤患者总生存期和黑色素瘤特异性生存期较差,而IIIC期患者总生存期较差但黑色素瘤特异性生存期无显著差异。

研究设计与样本

  • 回顾性双中心队列研究,纳入1998年至2019年诊断为侵袭性皮肤黑色素瘤的患者,共5216例,其中108例(2.1%)在初始分期时存在微卫星灶。

主要发现

  • 微卫星灶是总生存期较差的独立危险因素,风险比为1.57。
  • 微卫星灶是黑色素瘤特异性生存期较差的独立危险因素,风险比为1.76。
  • 微卫星灶是无病生存期较差的独立危险因素,风险比为1.76。
  • 伴有微卫星灶的IIIB期黑色素瘤患者5年总生存率为35%(95%CI,17.3%-73.4%)。
  • 伴有微卫星灶的IIIB期黑色素瘤患者5年黑色素瘤特异性生存率为45%(95%CI,23.1-87.5)。

局限性

  • 研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited information on microsatellite survival outcomes in patients with melanoma. OBJECTIVE: To evaluate survival outcomes in patients with microsatellites, assess their role within stage III stratification of the American Joint Committee on Cancer classification, and assess the results of sentinel lymph node biopsies in patients with microsatellites. METHODS: A retrospective bicenter cohort study from 1998 to 2019 included patients with a diagnosis of invasive cutaneous melanoma. RESULTS: Of a total of 5216 patients, 108 (2.1%) had microsatellites at initial staging. Survival analysis showed that microsatellites were an independent risk factor with decreased overall survival (OS), melanoma-specific survival (MSS), and disease-free survival, with hazard ratios of 1.57, 1.76, and 1.76, respectively. Stratified analysis in patients with stage III melanoma showed a 5-year OS of 35% (95% CI, 17.3%-73.4%) and a MSS of 45% (95% CI, 23.1-87.5) for patients with stage IIIB melanoma with microsatellites. LIMITATIONS: Retrospective design of the study. CONCLUSION: Microsatellites were associated with other adverse melanoma prognostic factors. A multivariate Cox regression analysis showed that they are an independent risk factor for worse OS, MSS, and disease-free survival. Patients with stage IIIB melanoma with microsatellites had worse OS and MSS, whereas patients with stage IIIC melanoma had worse OS but not MSS.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Riquelme-Mc Loughlin C, Sandoval-Clavijo A, Blanco de Tord M, et al. Prognostic role of microsatellites in melanoma and implications in the American Joint Committee on Cancer classification system: A cohort study. J Am Acad Dermatol. 2022. PMID: 36265824. doi:10.1016/j.jaad.2022.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。